Trial · NCT06793189
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
NCT06793189, Phase 2, Recruiting, Ruijin Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL. Trials, record NCT06793189. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06793189
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
- NCT number
- NCT06793189
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 145 participants, estimated
- Lead sponsor
- Ruijin Hospital
- Conditions
- Marginal Zone Lymphoma(MZL)
- Interventions
- Obinutuzumab and Orelabrutinib, Obinutuzumab, Orelabrutinib and Lenalidomide, Orelabrutinib, Orelabrutinib
- First posted
- 2025-01-27
- Last updated
- 2026-03-24
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 2-year progression-free survival | Baseline up to data cut-off (up to 24 months). | Progression-free survival is defined as the time from registration to the first occurrence of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first; as assessed by the investigator. |
| Secondary | Complete Response Rate after 6 cycles, at 12 months and 24 months | At the end of cycle 6, at 12 months and 24 months after treatment start. | The proportion of patients with complete response after 6 cycles, 12 months and 24 months from treatment start, according to the 2014 Lugano Response Criteria. |
| Secondary | Overall Response Rate after 6 cycles, at 12 months and 24 months | At the end of cycle 6, at 12 months and 24 months after treatment start. | The proportion of patients with complete and partial response after 6 cycles, 12 months and 24 months from treatment start, according to the 2014 Lugano Response Criteria. |
| Secondary | Treatment-Related Adverse Events rate as assessed by CTCAE version 5.0 | From enrollment to study completion (up to approximately 24 months). | |
| Secondary | Duration of Response (DOR) | From enrollment to study completion (up to approximately 24 months). | Duration of response is defined as the period from the first response (at least PR) to treatment until evidence of disease progression, relapse or death of any cause. |
| Secondary | Histological transformation rate | From enrollment to study completion (up to approximately 24 months). | Histological transformation rate is defined as the proportion of patients with histological transformation. |
| Secondary | 2-year overall survival | Baseline up to data cut-off (up to 24 months). | Overall survival is defined as the time from registration to death from any cause. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06793189
GET https://conductscience.org/api/trials/v1/NCT06793189/registered